Document Detail


Risk/benefit profile of arsenic trioxide.
MedLine Citation:
PMID:  11331438     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Approximately 20%-30% of patients with acute promyelocytic leukemia (APL) who are treated with the current standard all-trans retinoic acid and anthracycline-based chemotherapy regimen suffer relapse. In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positive safety and efficacy outcomes of a smaller 12-patient pilot study. Common adverse events were hyperleukocytosis, APL differentiation syndrome, prolonged QT interval on electrocardiogram, skin rash, and hyperglycemia.
Authors:
D M Rust; S L Soignet
Related Documents :
8820798 - Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblas...
1057948 - Immunotherapy for acute myelogenous leukemia.
2403818 - Etoposide in acute nonlymphocytic leukemia. australian leukemia study group.
1453128 - Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive cours...
23833308 - Phase ii study of bevacizumab in combination with sorafenib in recurrent glioblastoma (...
24997618 - The effect of tlx3 expression on the prognosis of pediatric t cell acute lymphocytic le...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The oncologist     Volume:  6 Suppl 2     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2001  
Date Detail:
Created Date:  2001-05-01     Completed Date:  2001-07-05     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  29-32     Citation Subset:  IM    
Affiliation:
Acute Care Nurse Practitioner Program (Oncology Subspecialty), School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents* / adverse effects,  therapeutic use
Arsenicals* / adverse effects,  therapeutic use
Humans
Leukemia, Promyelocytic, Acute / drug therapy*
Neoplasm Recurrence, Local
Oxides* / adverse effects,  therapeutic use
Risk Assessment
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Arsenicals; 0/Oxides; 1327-53-3/arsenic trioxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer...
Next Document:  Anterior rectocele due to obstructed defecation relieved by botulinum toxin.